Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Vibecotamab · XMAB-14045

Bispecific antibody · Immune activation, directed at CD123 (interleukin-3 receptor alpha chain) (IL3RA) and CD3 complex (CD3E) · developed by Xencor

Phase 1 Most advanced trial (none active)
XNCR Developer
1 Registered trials

What is Vibecotamab?

Vibecotamab is a bispecific monoclonal antibody that binds CD123 on tumor cells and the CD3 complex on T cells, crosslinking cytotoxic T lymphocytes to CD123-expressing cells to trigger their lysis. It retains most of the native Fc domain, which prolongs half-life. It is studied in acute myelogenous leukemia, B-cell acute lymphoblastic leukemia, blastic plasmacytoid dendritic cell neoplasm, and chronic myeloid leukemia in blast crisis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
XMAB-14045
Drug type
Bispecific antibody
Targets
CD123 (interleukin-3 receptor alpha chain) (IL3RA), CD3 complex (CD3E)
Mechanism
Immune activation, directed at CD123 (interleukin-3 receptor alpha chain) (IL3RA) and CD3 complex (CD3E)
Pathways
T-cell mediated cytotoxicity, CTL-mediated tumor cell lysis
Therapy area
Oncology
Developer
Xencor, Inc. (XNCR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
JD56EJA59S

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02730312 Phase 1 Acute Myelogenous Leukemia Completed XNCR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myelogenous LeukemiaB-cell Acute Lymphoblastic LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmChronic Myeloid Leukemia, Blast Crisis

Other drugs acting on IL3RA / CD3E

More from Xencor

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.

Follow XNCR, the company behind Vibecotamab

See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XNCR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.